Ecuador Medical Device Imports 2026: Customs Duty, IVA, FODINFA and ISD Tax Structure
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The tax burden on medical device imports into Ecuador follows a four-layer structure: ad valorem customs duty (determined by the tariff code), value added tax (IVA) at 15% (on a base of CIF plus duty), the Fund for the Integral Development of Children (FODINFA) at 0.5% (on the CIF value), and the tax on the outflow of foreign currency (ISD) at 5% (on outward payments). Medical devices are not covered by the general IVA exemption, and the burden must be calculated tariff code by tariff code.
2. Legal basis
| Regulation | Reference number | Publication date | Provision / nature |
|---|---|---|---|
| Internal Tax Regime Law | Ley de Régimen Tributario Interno, as amended | Current version | IVA rate provisions |
| IVA rate adjustment | Raised from 12% to 15% | In force 2024-04-01 | Rate adjustment provisions |
| Fund for the Integral Development of Children (FODINFA) | Created in 2006 | Current version | Rate of 0.5%, assessed on the CIF value |
| Tax on the outflow of foreign currency (ISD) | Impuesto a la Salida de Divisas | Current version | Rate of 5% |
| Health Law | Ley 67/2006, Registro Oficial Suplemento 423 | 2006-12-22 | Article 132 (health surveillance and control) |
Verification status note: the rates described in this article are drawn from public materials of the Internal Revenue Service (SRI) and the National Customs Service (SENAE) as consistently cited by professional bodies. Specific article numbers for each rate should be cross-checked a second time against the official texts currently published by SRI and SENAE. The effective rate for each medical device tariff code must be calculated separately against the specific HS classification, because duty rates vary widely across device categories and a category-level assumption is not reliable for budgeting.
3. Expert insights
Insight 1: The four layers rest on different tax bases, and the calculation order cannot be rearranged. Each layer is computed against its own base and administered under its own rules, so a model that collapses them into a single percentage of the CIF value will drift as soon as any one rate changes.
- Ad valorem customs duty: the rate is set by the HS tariff code and is assessed on the CIF value;
- IVA at 15%: assessed on a base of CIF plus customs duty;
- FODINFA at 0.5%: assessed on the CIF value;
- ISD at 5%: assessed on outward payments abroad.
The correct calculation order is therefore: fix the tariff code first, then compute the duty, then IVA, then add FODINFA, and finally apply ISD.
Insight 2: The rise of IVA from 12% to 15% is the most significant cost variable in recent years. The adjustment took effect on 2024-04-01 and directly raises the landed cost of all imported medical devices. This change is not reflected in most Chinese-language reference materials published earlier. On a typical CIF value, the three-point increase compounds with the duty in the IVA base, so the effective impact on the landed cost is slightly larger than three points of the CIF value alone, which is why older costing sheets systematically understate current import cost.
Insight 3: Medical devices are generally absent from the general IVA exemption list. Goods on specific schedules may apply a 0% rate, but medical devices are typically not among them, and each tariff code must be confirmed individually. This is the assumption most often gotten wrong in pricing models. Quotations prepared abroad that assume exempt treatment arrive in Ecuador with a fifteen-point gap against the actual invoice, and that gap is usually discovered after the goods are already in the port system, when the importer has little room to renegotiate.
Insight 4: The ISD is a tax burden specific to Ecuador. The tax on the outflow of foreign currency applies to payments made abroad at a rate of 5%. For exporters from the Chinese mainland settling in US dollars, the ISD is borne by the Ecuadorian importer, but it materially affects that party’s willingness to buy and the room available in quotations.
Insight 5: Taxation and the registration system belong to separate lines. Sanitary registration is administered by ARCSA (Article 5), while taxation is administered by SRI and SENAE. Holding a registration certificate confers no tax relief of any kind, and companies must model the burden independently. In practice the two lines intersect only operationally: the registration certificate and the import permit documents are among the papers handled at clearance, but they have no effect on the duty, IVA, FODINFA or ISD that the customs system computes.
4. Practical recommendations
- Fix the HS tariff code during the registration phase already, leaving lead time for the tax calculation.
- Build the quotation model in the order CIF, duty, IVA, FODINFA, ISD, to avoid errors in the tax bases.
- Confirm the IVA rate applicable to the tariff code with SRI, and do not assume that medical devices enjoy an exemption.
- List the ISD explicitly in the importer’s cost sheet, and address it early in commercial negotiations.
- Review the rates once a year, since IVA and duty rates change more frequently than in most markets, and a stale rate propagates through every open quotation.
5. Verification checklist
- □ The exact HS tariff code of each product for import has been determined
- □ A full landed cost model has been built on the four-layer structure
- □ The IVA rate for the tariff code has been confirmed with SRI
- □ The ISD has been listed in the importer’s cost sheet
- □ An annual rate review mechanism has been set up
- □ It has been confirmed that the registration certificate confers no tax relief
Regulatory information verified as of October 29, 2026
GRZAN service note
GRZAN provides regulatory support in this country for medical device manufacturers, importers and authorized representatives, covering registration pathway planning, HS classification support for tax modeling, licensing structure design, official fee and timeline estimation, technical dossier preparation, and post-market compliance management. Manufacturers and importers modeling the landed cost of Ecuador imports may contact GRZAN at info@grzanglobal.com for a tailored solution.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us